Justification for routine screening of pharmaceutical products in immune function tests: A review of the recommendations of Putman et al. (2003)

Fundamental and Clinical Pharmacology

Volumn 19, Issue 3, 2005, Pages 317-322

  Ryle, Peter R ^a  

^a PR BioServices Ltd   (United Kingdom)

Author keywords

Immunotoxicity; Opioids; Pharmaceuticals; Salmeterol; Toxicity testing

Indexed keywords

AMOXICILLIN; BUPRENORPHINE; CIMETIDINE; FUROSEMIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHADONE; MORPHINE DERIVATIVE; OPIATE DERIVATIVE; SALMETEROL;

CLINICAL TRIAL; DIAGNOSTIC ERROR; DRUG CROSS REACTIVITY; DRUG MEGADOSE; DRUG SCREENING; EVALUATION; EVIDENCE BASED MEDICINE; HUMAN; IMMUNE FUNCTION TEST; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANIMALS; BUPRENORPHINE; DRUG EVALUATION, PRECLINICAL; GUIDELINES; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY; METHADONE; MORPHINE; NARCOTICS; PHARMACEUTICAL PREPARATIONS;

EID: 20044394262     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2005.00337.x     Document Type: Review

References (16)

1. Committee for Proprietary Medicinal Products. CPMP note for guidance on repeated dose toxicity. CPMP/SWP/1042/99. CPMP. London. 2000.
2. FDA. Guidance for industry: immunotoxicology evaluation of investigational new drugs. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. Rockville, MD 20857, USA, 2002.
3. Putman E., van der Laan J.W., van Loveren H. Assessing immunotoxicity: guidelines. Fundam. Clin. Pharmacol. (2003) 17 615-626.
4. Dean J.H., Hinks J.R., Remandet B. Immunotoxicology assessment in the pharmaceutical industry. Toxicol. Lett. (1998) 102-103 247-255.
5. Chapel H.M. Consensus on diagnosis and management of primary antibody deficiencies. Br. Med. J. (1994) 309 581-585.
6. de Waal E.J., de Jong W.H., van der Vliet H., Verlaan B., van Loveren H. An immunotoxicity screening study on salmeterol in rats. Int. J. Immunopharmacol. (1996) 18 523-528.
7. de Waal E.J., de Jong W.H., van der Stappen A.J., Verlaan B., van Loveren H. Effects of salmeterol on host resistance to Trichinella spiralis in rats. Int. J. Immunopharmacol. (1999) 21 523-529.
8. Taverne J., Bradley J.E. Immunity to protozoa and worms, in: Roitt I., Brostoff J., Male D. (Eds). Immunology. 5th edn, Mosby, London, 1998. pp. 243-262.
9. Dollery C. Salmeterol. in: Collery C. (Ed.). Therapeutic drugs, 2nd edn, Churchill Livingstone, London, 1999, pp. S3-S7.
10. Dowling R.B., Cole J.M., Cole P.J., Wilson R. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur. Respir. J. (1998) 11 86-90.
11. de Waal E.J., van der Laan J.W., van Loveren H. Effects of prolonged exposure to morphine and methadone on in vivo parameters of immune function in rats. Toxicology (1998) 129 201-210.
12. van Loveren H., Gianotten N., Hendriksen C.F.M., Schuurman H.J., van der Laan J.W. Assessment of immunotoxicity of buprenorphine. Lab. Anim. (1994) 28 355-363.
13. WHO Scientific Group. Primary immunodeficiency diseases. Report of a WHO Scientific Group. Immunodefic. Rev. (1992) 3 195-236.
14. LeBrec H., Blot C., Pequet S., Roger R., Bohuon C., Pallardy M. Immunotoxicological investigation using pharmaceutical drugs: in vivo evaluation of immune effects. Fundam. Appl. Toxicol. (1994) 23 159-168.
15. Snodin D. Regulatory immunotoxicology: does the published evidence support mandatory nonclinical immune function screening in drug development. Reg. Pharmacol. Toxicol. (2004) 40 336-355.
16. International Conference on Harmonisation (ICH). Draft (step 2) guideline for topic S8: immunotoxicology. Issued November 18, 2004. Available at: http://www.ich.org/MediaServer.jser?@_ID=1706&@_MODE=GLB